Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner
Clinical and Experimental Immunology · 06.01.2026 · 220 (1)
DOI: 10.1093/cei/uxag018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 30.03.2026. Verfasst von Mehri Hajiaghayi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, School of Health, Concordia University, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Nebivolol, Breast Neoplasms, Receptors, Adrenergic, beta-2, Cytotoxicity, Immunologic. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Fonds de recherche du Québec-Nature et technologies.
Abstract (Originalsprache)
Introduction
Cancers often drive T cells toward an exhausted state characterized by impaired cytotoxicity and upregulation of inhibitory receptors (PD-1, TIM-3, CD38) and transcriptional regulators (TOX, NFATc1). Repeated stimulation in vitro is used to model this process, reflecting chronic antigen exposure in the tumor microenvironment. Stress-derived catecholamines further drive dysfunction through β-adrenergic receptor (β-AR) signaling. Here, we examined the impact of nebivolol, an atypical β1-AR blocker with β2-biased agonist activity, on T-cell exhaustion and cytotoxicity against breast cancer cells.
Methods
Human CD3+ T cells from healthy participants were activated once (early activation) or four times (repeated activation) using CD3/CD28/CD2 T cell activator. Cells were treated in vitro with nebivolol, terbutaline (β2-agonist), isoproterenol (β1/β2-agonist), and metoprolol (β1-blocker). Exhaustion markers, including PD-1, TIM-3, CD38, and TOX, were measured by flow cytometry and RT-qPCR; NFATc1 by western blot; TNF and IFN-γ by ELISA, and cytotoxicity against MCF-7 breast carcinoma cells by co-culture assays. Disruption of the β2-AR gene (ADRB2) was achieved using CRISPR/Cas9.
Results
Nebivolol reduced the proportion of TIM-3+CD38+PD-1+ T cells, downregulated TOX and nuclear NFATc1, and restored ADRB2 expression under repeated activation conditions. Nebivolol enhanced TNF secretion and improved cytotoxicity against MCF-7 cells. In contrast, terbutaline and isoproterenol had no significant effect on exhaustion markers or cytotoxicity. Metoprolol did not inhibit nebivolol’s activity, indicating that its effects are not β1-AR-dependent. Disruption of ADRB2 indicated that nebivolol's anti-exhaustion effects are mediated by β2-AR.
Discussion
These findings show that nebivolol reinvigorates CD4+ and CD8+ T cells following repeated activation, restoring their cytotoxic function against breast cancer cells in vitro. The immunomodulatory activity of Nebivolol is independent of β1-AR and mediated through β2-AR, suggesting that biased β2-AR signaling may represent a potential strategy for modulating T cell exhaustion in the tumor microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, School of Health, Concordia University, Montréal, Québec, Canada.
- Department of Chemical and Materials Engineering, Center for Applied Synthetic Biology, Concordia University, Montréal, Québec, Canada.
- Department of Electrical and Computer Engineering, School of Health, Concordia University, Montréal, Québec, Canada.
- Department of Health Kinesiology & Applied Physiology, School of Health, Concordia University, Montréal, Québec, Canada.
ORCID-Profile: Mehri Hajiaghayi
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Fonds de recherche du Québec-Nature et technologies
Zitieren
APA
Hajiaghayi, M., Gholizadeh, F., Rahbari, N., Emamnia, N., Shih, S. C. C., & Darlington, P. J. (2026). Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag018
Vancouver
Hajiaghayi M, Gholizadeh F, Rahbari N, Emamnia N, Shih SCC, Darlington PJ. Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag018
BibTeX
@article{Hajiaghayi2026,
author = {Hajiaghayi, Mehri and Gholizadeh, Fatemeh and Rahbari, Niloufar and Emamnia, Negaralsadat and Shih, Steve C C and Darlington, Peter J},
title = {Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner},
journal = {Clinical and Experimental Immunology},
year = {2026},
volume = {220},
number = {1},
doi = {10.1093/cei/uxag018}
}
EUVIMED